Patient groups objected to the decision of the Cancer Drugs Benefit Appeal Committee on hold against Kymriah (Tisagenleclecel), which drew attention to insurance benefits as a cell therapy and a "one-shot treatment." This is because it is a new drug that is directly related to life for leukemia patients, and even though they have to be paid in a hurry through the fast track system, the progress is slow and causes pain. Korea Leukemia patients organization said it will submit a petition to the National Human Rights Commission of Korea on October 1.

Kymriah is the world's first CAR-T treatment licensed as efficacy and effect indication for treatment of recurrent or refractory B cell acute lymphocytic leuk